Navigation Links
New Report Provides Insight Into Developments in the Market for Anxiety and Depression Therapies

SCOTTSDALE, Ariz., Oct. 16 /PRNewswire/ -- MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published a new report providing critical strategic insight for pharma and biotech companies with a stake in the market for anxiety and depression therapies.

In this report, entitled "MedPredict Thought Leader Insight & Analysis: Anxiety & Depression," physician experts from North America and Europe discuss the strengths and weaknesses of a variety of branded and near-market antidepressants and anxiolytics.

"There have been some notable developments in the use of antipsychotics, and special emphasis on new classes -- including CRF and NK antagonists," according to Jeff Berk, MedPredict President. "The thesis of this panel is that there are two types of new drug launches that will be successful in the next five years. The first is augmentation strategies to SSRIs. Today this includes the use of low dose quetiapine. This time frame should also see the approval of the first NK and CRF antagonists." According to this report, monotherapy strategies will find a home mostly in the primary care setting after failure of a generic SSRI. In the community setting, safety will trump efficacy, and a parity claim with an improved side effect profile will win out.

The report also discusses the role of genomics, endophenotypes and biomarkers in the development of pharmacotherapies for depression.

Drugs/Companies mentioned in this report include: Effexor (venlafaxine; Wyeth), Lexapro (escitalopram; Forest), Pristiq (o-desmethylvenlafaxine; Wyeth), Cymbalta (duloxetine; Lilly), Wellbutrin (bupropion; GlaxoSmithKline), Valdoxan (agomelatine; Novartis/Servier), bifeprunox (Wyeth/Solvay/ Lundbeck), Seroquel (quietiapine; AstraZeneca), amibegron (Sanofi-Aventis), GSK-561679 (GSK), Pexacerfont (BMS-562086; Bristol-Myers Squibb), ONO-2333Ms (Ono), casopitant (GlaxoSmithKline), saredutant (Sanofi-Aventis), esmirtazapine (Organon / Schering-Plough), Nemifitide (Tetragenix), SSR241586 (Sanofi-Aventis), and many others.

This report can be purchased by contacting MedPredict. Members of the media may request an interview.

About MedPredict

MedPredict ( maintains a proprietary database of over 1,000 global physician thought leaders, including 40+ specialties in 30+ therapeutic categories. Based on primary interviews with these thought leaders, MedPredict publishes periodic reports in each category to keep clients up-to-date on emerging trends and competitive activity. The reports include thought leader reactions to recent publications and medical conferences, as well as clinical, regulatory and marketing activity.

SOURCE MedPredict
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. No harm in reducing prenatal check up to 3 - 6 times says WHO report
2. Autopsy reports could be valuable and informative
3. China reports declining number of SARS Cases
4. Russia Reports First SARS Case
5. Report on the Safety and Effectiveness of Melatonin supplements
6. WHO report asks for improved healthcare for mother and child
7. Research reports that c-section deliveries are rising
8. Jharkhand reports 13,000 Malaria cases
9. Sepsis Death Reported With Mifepristone – FDA Issues Warnin
10. Experts Insist That Neonatal Herpes Be Reported Regularly
11. Uganda Reports Failure To Contain Sleeping Sickness
Post Your Comments:
(Date:6/25/2016)... ... 25, 2016 , ... Experts from the American Institutes for ... Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. , AIR ... care planning, healthcare costs and patient and family engagement. , AIR researchers will ...
(Date:6/25/2016)... ... , ... "With 30 hand-drawn hand gesture animations, FCPX users can easily customize ... Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn pictures into ... Simply select a ProHand generator and drag it above media or text in the ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin ... injury. Recently, he has implemented orthobiologic procedures as a method for treating his ... of the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June ... with. The article goes on to state that individuals are now more comfortable seeking ... common operations such as calf and cheek reduction. The Los Angeles area medical group, ...
(Date:6/24/2016)... ... 2016 , ... Marcy was in a crisis. Her son James, eight, was out of control. ... and physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. ... rocks at my other children and say he was going to kill them. If ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... CHAPEL HILL, N.C. , June 24, 2016 ... in healthcare decisions and regulators/payers have placed more ... this new environment, patient support programs in the ... support for patients, medications. Consequently, pharmaceutical companies are ... to ensure they are providing products and services ...
(Date:6/24/2016)... June 24, 2016  Global Blood Therapeutics, Inc. (GBT) ... developing novel therapeutics for the treatment of grievous ... the closing of its previously announced underwritten public ... the public offering price of $18.75 per share. ... offered by GBT. GBT estimates net proceeds from ...
(Date:6/24/2016)... , June 24, 2016 ... Markets has announced the addition of the " ... offering. This ... and provides an updated review, including its applications in ... the total market, which includes three main industries: pharmaceutical ...
Breaking Medicine Technology: